Guardigni V, Fabbri G, Grilli A, Contini C

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 404-408
Archivo PDF: 77.79 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatology 2011; 55: 245-64.

2. Mecenate F, Pellicelli AM, Barbaro G, Romano M, Barlattani A, Mazzoni E, Bonaventura ME, et al. Club Epatologi Ospedalieri (CLEO) Group. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. BMC Gastroenterology 2010; 10: 21.

3. Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiology 2006; 1: 103-12.

4. Germain DP. Clinical and genetic features of vascular Ehlers-Danlos syndrome. Annals of Vascular Surgery 2002; 16: 391-7.

5. Lind J, Wallenburg HC. Pregnancy and the Ehlers-Danlos syndrome: a retrospective study in a Dutch population. Acta Obstetricia et Gynecologica Scandinavica 2002; 81: 293-300.

6. Tassart S, Bernard P, Debieve F, Devylder M, Hubinont C. Dissection of renal artery aneurysm in a pregnant woman with Elhers-Danlos disease type IV. Journal de Gynécologie, Obstetrique et Biologie De La Reproduction 2006; 35: 275-9.

7. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup R. Ehlers-Danlos syndromes: revised nosology, Villefranche. Am J Medical Genetics 1998; 77: 31-7.

8. Iurassic S. Hypermobile syndrome: functional and aesthetic damages. Observations on 50 cases. La Medicina Del Lavoro 2004; 95: 223-32.

9. Bacon BR, McHutchison JG. Treatment issue with chronic hepatitis C: special population and pharmacy strategies. The American Journal of Managed Care 2005; 11: 296-306.

10. Stribling R, Sussman N, Vierling JM. Treatment of hepatitis C infection. Gastroenterology Clinics of North America 2006; 35: 463-86.

11. Kamholz J, Menichella D, Jani A, Garbern J, Lewis RA, Krajewski KM, Lilien J, et al. Charcot-Marie-Tooth disease type 1: Molecular pathogenesis to gene therapy. Brain 2000; 123: 222-33.

12. Shy ME. Charcot–Marie–Tooth disease: an update. Current Opinion in Neurology 2004; 17: 579-85.

13. Irobi J, Van Impe K, Seeman P, Jordanova A, Dierick I, Verpoorten N, Michalik A, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nature Genetics 2004; 36: 597-601.

14. Niemann A, Berger P, Suter U. Pathomechanisms of Mutant Proteins in Charcot-Marie-Tooth Disease. Neuromolecular Medicine 2006; 8: 217-42.

15. Yoon MS, Obermann M, Dockweiler C, Assert R, et al. Sensory neuropathy in patients with cryoglobulin negative hepatitis C infection. J Neurology 2011; 258: 80-8.

16. Nemni R, Sanvito L, Quattrini A, Santuccio G, Camerlingo M, Canal M. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurology Neurosurgery and Psychiatry 2003; 74: 1267–71.

17. Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon á 2a therapy for chronic hepatitis C virus infection. World J Gastroenterology 2008; 14: 318-21.

18. Santoro L, Manganelli F, Briani C, Giannini F, Benedetti L, Vitelli E, Mazzeo A, et al. HCV Peripheral Nerve Study Group. HCV Peripheral Nerve Study Group, Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. J Neurology Neurosurgery and Psychiatry 2006; 77: 626-9.

19. Brannagan TH 3rd. Current treatments of chronic immune- mediated demyelinating polyneuropathies. Muscle & Nerve 2009; 39: 563-78.

20. National Institute of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-S20.